Drug Trial Radar · NCT02630706
A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)
Last checked: Nov 20, 2026Latest source record: Dec 7, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
506
Actual
Start
Dec 16, 2015
Primary completion
Dec 27, 2017
Study completion Dec 27, 2017
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Dec 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin monotherapy. The primary hypothesis is that the mean reduction from baseline in HbA1C for 15 mg and 5 mg ertugliflozin (tested sequentially) is greater than for placebo.
Conditions
- Type 2 Diabetes Mellitus
Interventions
Ertugliflozin 5 mgDrug
Ertugliflozin 5 mg oral tablet taken once daily
Ertugliflozin 15 mgDrug
Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
Placebo matching ertugliflozinDrug
Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
MetforminDrug
Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
GlimepirideDrug
Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)Time frame: Baseline and Week 26
- Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)Time frame: Baseline and Week 26
- Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)Time frame: Up to 28 weeks
- Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)Time frame: Up to 28 weeks
- Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)Time frame: Up to 26 weeks
- Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)Time frame: Up to 26 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.